CA2651755A1 - Methods and compositions for the diagnosis and treatment of cancer - Google Patents

Methods and compositions for the diagnosis and treatment of cancer Download PDF

Info

Publication number
CA2651755A1
CA2651755A1 CA002651755A CA2651755A CA2651755A1 CA 2651755 A1 CA2651755 A1 CA 2651755A1 CA 002651755 A CA002651755 A CA 002651755A CA 2651755 A CA2651755 A CA 2651755A CA 2651755 A1 CA2651755 A1 CA 2651755A1
Authority
CA
Canada
Prior art keywords
fgfr2
antibody
gene
antagonist
colorectal cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002651755A
Other languages
English (en)
French (fr)
Inventor
John Chant
Anthony S. Guerrero
Peter Haverty
Cynthia Honchell
Kenneth Jung
Thomas Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2651755A1 publication Critical patent/CA2651755A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002651755A 2006-05-12 2007-05-11 Methods and compositions for the diagnosis and treatment of cancer Abandoned CA2651755A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79977206P 2006-05-12 2006-05-12
US60/799,772 2006-05-12
PCT/US2007/068737 WO2007134210A2 (en) 2006-05-12 2007-05-11 Methods and compositions for the diagnosis and treatment of cancer

Publications (1)

Publication Number Publication Date
CA2651755A1 true CA2651755A1 (en) 2007-11-22

Family

ID=38694721

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002651755A Abandoned CA2651755A1 (en) 2006-05-12 2007-05-11 Methods and compositions for the diagnosis and treatment of cancer

Country Status (5)

Country Link
US (2) US8945572B2 (https=)
EP (1) EP2018442A2 (https=)
JP (1) JP2009536834A (https=)
CA (1) CA2651755A1 (https=)
WO (1) WO2007134210A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
JP2009536834A (ja) * 2006-05-12 2009-10-22 ジェネンテック・インコーポレーテッド 癌の診断及び治療のための方法及び組成物
EP2318529B1 (en) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
HUE035700T2 (en) * 2008-11-07 2018-05-28 Galaxy Biotech Llc Monoclonal antibodies to Fibroblast Growth Factor receptor 2
US20100136560A1 (en) * 2008-12-02 2010-06-03 The Johns Hopkins University Integrated Analyses of Breast and Colorectal Cancers
US20120301482A1 (en) * 2009-08-25 2012-11-29 National Jewish Health Methods and compositions for treatment of lung injury
US8445445B2 (en) 2009-09-15 2013-05-21 Five Prime Therapeutics, Inc. Method of promoting hair growth using FGFR4 extracellular domains
LT2498799T (lt) 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
RU2012153241A (ru) * 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
EP2723924A4 (en) * 2011-06-22 2015-03-25 Oncocyte Corp METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER
CN107823630A (zh) 2011-11-14 2018-03-23 戊瑞治疗有限公司 治疗癌症的方法
SG11201403085PA (en) * 2011-12-14 2014-10-30 Seattle Genetics Inc Fgfr antibody drug conjugates (adcs) and the use thereof
US20150191791A1 (en) * 2012-07-05 2015-07-09 Lsip, Llc Fgfr2 fusion gene
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9415118B2 (en) 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
KR102516152B1 (ko) 2013-08-01 2023-03-31 파이브 프라임 테라퓨틱스, 인크. 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체
MX2018006181A (es) * 2015-11-23 2018-09-24 Five Prime Therapeutics Inc Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
PT3624837T (pt) 2017-05-16 2025-10-01 Five Prime Therapeutics Inc Anticorpos anti-fgfr2 em combinação com agentes quimioterapêuticos no tratamento do cancro

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863888A (en) * 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
US6900053B2 (en) 2001-09-14 2005-05-31 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 2 expression
JP2002505431A (ja) * 1998-02-25 2002-02-19 アメリカ合衆国 迅速な分子プロファイリングのための細胞アッセイ法
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
WO2000024940A1 (en) * 1998-10-28 2000-05-04 Vysis, Inc. Cellular arrays and methods of detecting and using genetic disorder markers
CA2355215A1 (en) 1998-12-28 2000-07-06 Jim Wells Identifying small organic molecule ligands for binding
IL128380A0 (en) 1999-02-04 2000-01-31 Yeda Res & Dev A method of screening for agonists and antagonists of FGFR
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US6703495B2 (en) * 2000-06-07 2004-03-09 Lexicon Genetics Incorporated Polynucleotides encoding human transporter protein
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7537905B2 (en) * 2003-01-15 2009-05-26 The Regents Of The University Of California Amplified and overexpressed gene in colorectal cancers
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
EP1697420A2 (en) 2003-12-19 2006-09-06 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
WO2005115363A2 (en) 2004-05-25 2005-12-08 Yale University Method for treating skeletal disorders resulting from fgfr malfunction
CA2604844A1 (en) * 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
JP2009536834A (ja) 2006-05-12 2009-10-22 ジェネンテック・インコーポレーテッド 癌の診断及び治療のための方法及び組成物

Also Published As

Publication number Publication date
US20090311250A1 (en) 2009-12-17
EP2018442A2 (en) 2009-01-28
WO2007134210A8 (en) 2009-07-30
US8945572B2 (en) 2015-02-03
JP2009536834A (ja) 2009-10-22
WO2007134210A3 (en) 2008-03-20
US20150167101A1 (en) 2015-06-18
WO2007134210A2 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
US8945572B2 (en) Methods and compositions for the diagnosis and treatment of cancer
AU2007319214B2 (en) Genetic variations associated with tumors
US20090324595A1 (en) Cancer prognostic diagnostic and treatment methods
JP5596975B2 (ja) 腫瘍と関連している遺伝的変異
US20150376289A1 (en) Methods and compositions for the diagnosis and treatment of cancer
EP2041320B1 (en) Methods and compositions for the diagnosis and treatment of cancer
HK1108924B (en) Cancer prognostic methods

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20160126